Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judy L Thompson

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Biological Psychiatry|May 4, 2010
Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patientsDaniel R Rosell, Judy L Thompson, Mark Slifstein, et al.
Journal of Psychopharmacology (Oxford, England)|March 12, 2016
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophreniaRagy R Girgis, Jared X Van Snellenberg, Andrew Glass, et al.
Psychopharmacology|June 24, 2020
Amphetamine-induced striatal dopamine release in schizotypal personality disorderJudy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
JAMA Psychiatry|February 5, 2015
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging studyMark Slifstein, Elsmarieke van de Giessen, Jared Van Snellenberg, et al.
NPJ Schizophrenia|May 18, 2021
Increased face detection responses on the mooney faces test in people at clinical high risk for psychosisSteven M Silverstein, Judy L Thompson, James M Gold, et al.
Schizophrenia (Heidelberg, Germany)|May 12, 2025
Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlatesTanya Tran, Brian P Keane, Judy L Thompson, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Biological Psychiatry|May 4, 2010
Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patientsDaniel R Rosell, Judy L Thompson, Mark Slifstein, et al.
Journal of Psychopharmacology (Oxford, England)|March 12, 2016
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophreniaRagy R Girgis, Jared X Van Snellenberg, Andrew Glass, et al.
Psychopharmacology|June 24, 2020
Amphetamine-induced striatal dopamine release in schizotypal personality disorderJudy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
JAMA Psychiatry|February 5, 2015
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging studyMark Slifstein, Elsmarieke van de Giessen, Jared Van Snellenberg, et al.
NPJ Schizophrenia|May 18, 2021
Increased face detection responses on the mooney faces test in people at clinical high risk for psychosisSteven M Silverstein, Judy L Thompson, James M Gold, et al.
Schizophrenia (Heidelberg, Germany)|May 12, 2025
Increased face perception in individuals at clinical high-risk for psychosis: mechanisms, sex differences, and clinical correlatesTanya Tran, Brian P Keane, Judy L Thompson, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Pageof 5